Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARISTOTLE rectal cancer chemoradiation trial
ISRCTN09351447Phase 3Completed
- Sponsor
- Cancer Research UK
- Start
- Oct 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and irinotecan in rectal adenocarcinoma (2 arms), sponsored by Cancer Research UK. Primary endpoint: Disease-free survival. Started Oct 2011; status: completed.
02
Drugs
capecitabineirinotecan
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ISRCTN09351447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN09351447.